Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (BEIGF) Revenue (2016 - 2025)

Historic Revenue for BeOne Medicines (BEIGF) over the last 11 years, with Q3 2025 value amounting to $1.4 billion.

  • BeOne Medicines' Revenue rose 4100.29% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.0 billion, marking a year-over-year increase of 4992.31%. This contributed to the annual value of $3.8 billion for FY2024, which is 5496.48% up from last year.
  • BeOne Medicines' Revenue amounted to $1.4 billion in Q3 2025, which was up 4100.29% from $1.3 billion recorded in Q2 2025.
  • Over the past 5 years, BeOne Medicines' Revenue peaked at $1.4 billion during Q3 2025, and registered a low of $150.0 million during Q2 2021.
  • Over the past 5 years, BeOne Medicines' median Revenue value was $605.9 million (recorded in 2021), while the average stood at $668.7 million.
  • Its Revenue has fluctuated over the past 5 years, first soared by 106381.8% in 2021, then crashed by 4939.1% in 2022.
  • Quarter analysis of 5 years shows BeOne Medicines' Revenue stood at $214.0 million in 2021, then surged by 77.63% to $380.1 million in 2022, then surged by 66.91% to $634.4 million in 2023, then soared by 77.78% to $1.1 billion in 2024, then grew by 25.22% to $1.4 billion in 2025.
  • Its last three reported values are $1.4 billion in Q3 2025, $1.3 billion for Q2 2025, and $1.1 billion during Q1 2025.